Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 424B5: Prospectus
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BIENAIME JEAN JACQUES
Keros Therapeutics | 3: Initial statement of beneficial ownership of securities-Director BIENAIME JEAN JACQUES
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GORDON CARL L
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GRAY MARY ANN
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Knowles Julius
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nussbaum Ran
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kariv Tomer
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Seth Alpna
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Farzan Nima
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 8-K: Current report
Keros Therapeutics | 10-Q: Quarterly report
Keros Therapeutics | 8-K: Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Keros Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
No Data